The latest price target for Cadrenal Therapeutics (NASDAQ: CVKD) was reported by HC Wainwright & Co. on November 20, 2023. The analyst firm set a price target for $3.00 expecting CVKD to rise to within 12 months (a possible 552.17% upside). 1 analyst firms have reported ratings in the last year.

The latest analyst rating for Cadrenal Therapeutics (NASDAQ: CVKD) was provided by HC Wainwright & Co., and Cadrenal Therapeutics initiated their buy rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Cadrenal Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Cadrenal Therapeutics was filed on November 20, 2023 so you should expect the next rating to be made available sometime around November 20, 2024.

While ratings are subjective and will change, the latest Cadrenal Therapeutics (CVKD) rating was a initiated with a price target of $0.00 to $3.00. The current price Cadrenal Therapeutics (CVKD) is trading at is $0.46, which is within the analyst's predicted range.